Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.
Bilal HameedN A TerraultR M GillStephen CaldwellN ChalasaniJ H HoofnagleM L Van Nattanull nullPublished in: Alimentary pharmacology & therapeutics (2018)
OCA leads to weight loss in up to 44% of patients with NASH, and OCA therapy and weight loss have additive benefits on serum aminotransferases and histology. However, favourable effects of weight loss on alkaline phosphatase, lipids and blood glucose seen in placebo-treated patients were absent or reversed on OCA treatment. These findings stress the importance of assessing concomitant metabolic effects of new therapies of NASH. Clinical trial number: NCT01265498.
Keyphrases
- weight loss
- bariatric surgery
- blood glucose
- glycemic control
- roux en y gastric bypass
- clinical trial
- gastric bypass
- newly diagnosed
- end stage renal disease
- chronic kidney disease
- ejection fraction
- weight gain
- obese patients
- type diabetes
- prognostic factors
- body mass index
- double blind
- patient reported outcomes
- phase iii
- phase ii
- fatty acid
- open label
- stress induced
- skeletal muscle
- mesenchymal stem cells
- bone marrow
- combination therapy
- patient reported